Compare Novavax Inc (NVAX) vs Zscaler Inc (ZS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Zscaler Inc — how do they compare? Novavax Inc trades at $12.69 (market cap $1.82B), while Zscaler Inc trades at $234 (market cap $35.35B). The key difference: Zscaler Inc is far larger — about 19.4× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Zscaler Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Zscaler Inc for 41 Days on average.
| NVAX | ZS | |
|---|---|---|
Market Cap | $1.82B | $35.35B |
Volume | 6,198,505 | 3,726,203 |
Sector | Health | Technology |
52-Week High | $12.56 | $336.27 |
52-Week Low | $6.22 | $118.05 |
Typical Hold Time | 59 Days | 41 Days |
Enterprise Value | $1.39B | $33.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
Zscaler (ZS) trades at $233.73, up 9.45% today, with a bullish technical outlook supported by moving averages and strong quarterly earnings beats. Revenue growth is robust, rising from $1.1B in 2022 to $2.67B in 2025, though the company remains unprofitable with a net margin of -1.88%. Recent news includes a CRO transition and an upcoming Investor Day, while analyst sentiment is overwhelmingly positive with 79.6% buy ratings.
The stock offers growth potential driven by cybersecurity demand and AI product adoption, but risks include persistent losses, high valuation multiples, and competitive pressures. The consensus price target of $222.83 suggests modest downside from current levels, requiring careful risk assessment amid volatile market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Zscaler Inc
Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →
